These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22560366)

  • 1. Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: implications for radiotherapy.
    Bollineni VR; Wiegman EM; Pruim J; Groen HJ; Langendijk JA
    Cancer Treat Rev; 2012 Dec; 38(8):1027-32. PubMed ID: 22560366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
    Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
    Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes.
    Even AJ; van der Stoep J; Zegers CM; Reymen B; Troost EG; Lambin P; van Elmpt W
    Radiother Oncol; 2015 Aug; 116(2):281-6. PubMed ID: 26238010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.
    Trinkaus ME; Blum R; Rischin D; Callahan J; Bressel M; Segard T; Roselt P; Eu P; Binns D; MacManus MP; Ball D; Hicks RJ
    J Med Imaging Radiat Oncol; 2013 Aug; 57(4):475-81. PubMed ID: 23870348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer.
    Mac Manus MP; Hicks RJ
    Semin Nucl Med; 2012 Sep; 42(5):308-19. PubMed ID: 22840596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.
    Kjellsson Lindblom E; Ureba A; Dasu A; Wersäll P; Even AJG; van Elmpt W; Lambin P; Toma-Dasu I
    Med Phys; 2019 May; 46(5):2512-2521. PubMed ID: 30924937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapy.
    Ashley Cox R; Akhurst T; Bressel M; MacManus M; Ball D
    Radiother Oncol; 2017 Jul; 124(1):25-30. PubMed ID: 28662870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
    Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
    J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription.
    Ureba A; Lindblom E; Dasu A; Uhrdin J; Even AJG; van Elmpt W; Lambin P; Wersäll P; Toma-Dasu I
    Acta Oncol; 2018 Apr; 57(4):485-490. PubMed ID: 29141489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the hypoxic target volume based on positron emission tomography for image guided radiotherapy - the influence of the choice of the reference region and conversion function.
    Lindblom E; Dasu A; Uhrdin J; Even A; van Elmpt W; Lambin P; Wersäll P; Toma-Dasu I
    Acta Oncol; 2017 Jun; 56(6):819-825. PubMed ID: 28464740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric implications of the addition of 18 fluorodeoxyglucose-positron emission tomography in CT-based radiotherapy planning for non-small-cell lung cancer.
    Vinod SK; Kumar S; Holloway LC; Shafiq J
    J Med Imaging Radiat Oncol; 2010 Apr; 54(2):152-60. PubMed ID: 20518880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.
    Koh WJ; Bergman KS; Rasey JS; Peterson LM; Evans ML; Graham MM; Grierson JR; Lindsley KL; Lewellen TK; Krohn KA
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):391-8. PubMed ID: 7673026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular imaging of hypoxia in non-small-cell lung cancer.
    Yip C; Blower PJ; Goh V; Landau DB; Cook GJ
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):956-76. PubMed ID: 25701238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Image-guided adaptive radiotherapy in patients with locally advanced non-small cell lung cancer: the art of PET.
    Grootjans W; de Geus-Oei LF; Bussink J
    Q J Nucl Med Mol Imaging; 2018 Dec; 62(4):369-384. PubMed ID: 29869486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.
    Li L; Hu M; Zhu H; Zhao W; Yang G; Yu J
    Clin Lung Cancer; 2010 Sep; 11(5):335-40. PubMed ID: 20837459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer.
    Lavrenkov K; Partridge M; Cook G; Brada M
    Radiother Oncol; 2005 Oct; 77(1):1-4. PubMed ID: 16225943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.